MAPT and Alzheimer disease: On the basis of several pieces of evidence reporting thatAβ and tau are crucial partners that concurrently contributeto AD,131 the authors postulated that amolecular entity capable of concomitantly modulating targets thatembody the crucial points of these two pathways may represent a truedisease-modifying agent in AD therapy.